Aberdeen Group plc Decreases Stake in Guardant Health, Inc. $GH

Aberdeen Group plc cut its stake in Guardant Health, Inc. (NASDAQ:GH) by 33.2% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 115,701 shares of the company’s stock after selling 57,560 shares during the period. Aberdeen Group plc owned 0.09% of Guardant Health worth $7,229,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Sound Income Strategies LLC acquired a new stake in shares of Guardant Health during the third quarter worth $38,000. Allworth Financial LP lifted its holdings in shares of Guardant Health by 358.4% during the second quarter. Allworth Financial LP now owns 706 shares of the company’s stock worth $37,000 after purchasing an additional 552 shares during the period. Smartleaf Asset Management LLC boosted its position in Guardant Health by 162.2% in the third quarter. Smartleaf Asset Management LLC now owns 1,096 shares of the company’s stock valued at $68,000 after buying an additional 678 shares during the last quarter. FNY Investment Advisers LLC purchased a new stake in Guardant Health in the second quarter valued at approximately $62,000. Finally, Bayforest Capital Ltd purchased a new position in Guardant Health during the 3rd quarter worth approximately $78,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on GH. Morgan Stanley upped their target price on Guardant Health from $105.00 to $130.00 and gave the stock an “overweight” rating in a research note on Monday, December 1st. Evercore set a $110.00 price objective on Guardant Health in a research report on Friday. Wells Fargo & Company raised their price objective on shares of Guardant Health from $120.00 to $125.00 and gave the stock an “overweight” rating in a research note on Friday. TD Cowen boosted their target price on shares of Guardant Health from $130.00 to $135.00 and gave the company a “buy” rating in a research note on Friday. Finally, JPMorgan Chase & Co. increased their price target on shares of Guardant Health from $120.00 to $130.00 and gave the stock an “overweight” rating in a report on Friday. Twenty-one equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $117.43.

Key Headlines Impacting Guardant Health

Here are the key news stories impacting Guardant Health this week:

• Positive Sentiment: Multiple brokerages raised price targets and maintained buy/overweight ratings (Leerink to $180, JPMorgan to $130, Wells Fargo to $125, BTIG to $145, Canaccord to $135), signaling analyst confidence in upside from current levels. Analyst Raises Coverage
• Positive Sentiment: Q4 revenue beat and strong growth: Guardant reported $281.3M in Q4 revenue, +39% YoY and above consensus; management issued FY2026 revenue guidance around $1.3B, above Street expectations — a growth signal for core oncology testing. Press Release
• Positive Sentiment: Research coverage expansion: Robert W. Baird initiated coverage, which can broaden institutional interest and trading liquidity. Coverage Start
• Neutral Sentiment: Conference call and transcript available — provides detail on cadence of test volume, reimbursement progress and product roadmap; useful for digging into guidance assumptions. Earnings Transcript
• Neutral Sentiment: Market materials (slide deck, press release) posted for investors to verify segment trends and margin assumptions. Slide Deck / Press Release
• Neutral Sentiment: Short-interest data flagged a “significant increase” entry but shows 0 shares / NaN in the feed — the published data appears inconsistent, so short-interest impact is unclear. Short Interest Note
• Negative Sentiment: EPS miss: GAAP loss of ($0.50) vs. consensus (~($0.43)), which disappointed some investors despite revenue upside and may have pressured the stock near the close. Earnings Reaction
• Negative Sentiment: Management left EPS guidance effectively blank in the release (revenue guidance given but no numeric EPS target), which can create uncertainty around near-term profitability expectations. Guidance Details

Insider Transactions at Guardant Health

In other news, CFO Michael Brian Bell sold 80,362 shares of the stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $103.14, for a total value of $8,288,536.68. Following the completion of the sale, the chief financial officer directly owned 28,052 shares in the company, valued at $2,893,283.28. This represents a 74.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Chris Freeman sold 31,452 shares of the firm’s stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $103.07, for a total transaction of $3,241,757.64. Following the completion of the transaction, the insider directly owned 25,987 shares in the company, valued at approximately $2,678,480.09. This represents a 54.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 434,511 shares of company stock worth $45,580,887 in the last quarter. 6.10% of the stock is owned by insiders.

Guardant Health Stock Down 3.1%

GH stock opened at $103.10 on Friday. Guardant Health, Inc. has a 52 week low of $34.88 and a 52 week high of $120.74. The firm has a 50-day simple moving average of $106.69 and a 200-day simple moving average of $85.94. The stock has a market capitalization of $12.99 billion, a P/E ratio of -31.15 and a beta of 1.63.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings data on Thursday, February 19th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.07). The company had revenue of $281.27 million during the quarter, compared to the consensus estimate of $269.74 million. During the same quarter last year, the firm posted ($0.62) EPS. The company’s revenue was up 39.4% compared to the same quarter last year. On average, analysts expect that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.